54 results on '"Yang, Jeng-Fu"'
Search Results
2. FRI-271 Hepatitis C infection increases the risk of new-onset HTN and DM among patients with metabolic dysfunction-associated steatotic liver disease
3. Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease
4. The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan® CAP Values among the Taiwanese Population
5. Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease
6. A People-centered Decentralized Outreach Model Toward HCV Micro-elimination in hyperendemic areas: COMPACT Study in SARS Co-V2 pandemic
7. Epidemiology of Chronic Hepatitis B Infection in the Cohort of College Students with Vaccination in Taiwan
8. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes
9. Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan
10. A People-Centered Decentralized Outreach Model Toward HCV Micro-Elimination in Hyperendemic Areas: COMPACT Study in SARS Co-V2 Pandemic
11. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
12. Treatment efficacy for patients with chronic hepatitis C and preexisting hepatocellular carcinoma by directly acting antivirals
13. Higher NAFLD fibrosis score is associated with impaired eGFR
14. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis
15. Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR
16. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon‐free direct antiviral agents
17. Effect of music on level of anxiety in patients undergoing colonoscopy without sedation
18. Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan
19. Distinct subpopulations of hepatitis C virus infectious cells with different levels of intracellular hepatitis C virus core protein
20. The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases
21. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol
22. Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan
23. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication
24. Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
25. Occupational risks of esophageal cancer in Taiwanese men
26. Waist circumference, body mass index, serum uric acid, blood sugar, and triglyceride levels are important risk factors for abnormal liver function tests in the Taiwanese population
27. The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study
28. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy
29. Erratum to: “Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin” [J Hepatol 2012;56:34–40]
30. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy
31. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1
32. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
33. Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C
34. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients
35. Performance characteristics of a combined hepatitis C virus core antigen and anti–hepatitis C virus antibody test in different patient groups
36. Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection
37. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies – A multicenter prospective trial
38. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
39. Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study
40. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan
41. Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients
42. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection
43. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response
44. Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C
45. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: Some issues
46. Occupational Risks of Esophageal Cancer in Taiwanese Men
47. 1531: Carotid Arterial Stiffness Index Beta Was Affected by Histology Activity Index Score in Patients Infected with Hepatitis Virus B or C
48. Comparison of Clinical Application of the Abbott HBV PCR Kit and the Versant HBV DNA 3.0 Test to Measure Serum Hepatitis B Virus DNA in Taiwanese Patients
49. Hepatitis C Virus Infection And Metabolic Syndrome—A Community-Based Study in an Endemic Area of Taiwan
50. Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.